PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Files An 8-K Regulation FD Disclosure

Item 7.01.

Paratek Pharmaceuticals, Inc. (the Company) will be conducting
meetings with investors attending the 35^th Annual J.P.
Morgan Healthcare Conference in San Francisco, California
beginning on January 9, 2017. As part of these meetings, the
Company will deliver the slide presentation attached to this
report as Exhibit 99.1, which is incorporated herein by
reference.

The information in this report (including Exhibit 99.1) is being
furnished to Item 7.01 and shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor will it be incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific
referencing in such filing.

(d) Exhibits.

About PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company’s sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company’s other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Recent Trading Information

PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) closed its last trading session up +0.05 at 15.45 with 139,498 shares trading hands.